Lets look at ABH [Angel Biotechnology]
penny stocks are risky, but i believe they arent the quickest way to lose money...maybe highly leveraged forex trading can take over it easily... 😛 anywayz..
it all depends on ur investing style and ur risk profile... penny stocks are different from normal stocks becoz therez usually an 'IF' attached to the robustness of their business model and earnings growth... this is where the smart investor/analyst comes in...analyzing that 'IF' is challenging and highly rewarding...but with experience and extensive knowledge, i believe u can pick more good penny stocks than bad onez...
why not do a small exercise...letz pick a penny stock of ur choice and then analyze its 'IF' in detail...if not for anything, letz do it for the sake of knowledge n some experience...
My view on biotech and indeed research / intellectual property creating companies that don't have operating models i.e. don't generate revenue, is that what you are betting on is:
1. That research uncovers a potentially marketable drug
2. A biotech with a potentially marketable drug, once discovered, is a bet on navigating the clinical trials process.
Therefore there are 3 phases during which such stocks may appreciate in value. The first phase is research uncovering a potentially marketable drug, the second phase is advancement in the clinical trials process and the third phase is generally the prospect of the biotech entity being acquired by a larger pharmaceutical marketing concern e.g. Pfizer, Bristol Squib, Smith Klein.
It is very important to identify, which phase of development the company is at.
Without knowledge of the biotechnology, the key to this analysis is understanding the human capital allied with this operating concern. Specifically we are trying to determine whether the company has acquired talented researchers with a track record of bringing marketable products to market [in this way we are betting on the commercial judgement of the research heads] or if we are in the second phase, we are assessing management's ability or experience in navigating the clinical trials process or if we are in the final phase, management's ability to find an acquirer for their operating concern.
Now to the stock in question - I will outline my analysis in the next post.